Evercore ISI Issues Positive Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lifted by investment analysts at Evercore ISI from $10.00 to $12.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Evercore ISI’s price objective points to a potential upside of 65.98% from the stock’s current price.

BCRX has been the subject of several other reports. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.17.

BioCryst Pharmaceuticals Trading Down 8.8 %

Shares of BCRX opened at $7.23 on Monday. The stock’s 50-day moving average price is $7.60 and its two-hundred day moving average price is $7.60. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.88. The company has a market capitalization of $1.50 billion, a PE ratio of -11.85 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.19) earnings per share. Equities research analysts predict that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently made changes to their positions in BCRX. The Manufacturers Life Insurance Company grew its stake in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after buying an additional 86,571 shares during the period. Counterweight Ventures LLC boosted its holdings in BioCryst Pharmaceuticals by 591.7% in the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after acquiring an additional 79,884 shares in the last quarter. XTX Topco Ltd grew its stake in BioCryst Pharmaceuticals by 299.0% in the second quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after acquiring an additional 117,607 shares during the period. Seven Eight Capital LP increased its holdings in shares of BioCryst Pharmaceuticals by 1,407.1% during the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after acquiring an additional 158,358 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.